The Mental Health Research Institute, The University of Melbourne, Kenneth Myer Building, 30 Royal Parade, Parkville, Victoria, 3010, Australia.
Biomark Med. 2013 Aug;7(4):641-62. doi: 10.2217/bmm.13.59.
Alzheimer's disease (AD) is the most common cause of dementia in the elderly population and attempts to develop therapies have been unsuccessful because there is no means to target an effective therapeutic window. CNS biomarkers are insightful but impractical for high-throughput population-based screening. Therefore, a peripheral, blood-based biomarker for AD would significantly improve early diagnosis, potentially enable presymptomatic detection and facilitate effective targeting of disease-modifying treatments. The various constituents of blood, including plasma, platelets and cellular fractions, are now being systematically explored as a pool of putative peripheral biomarkers for AD. In this review we cover some less known peripheral biomarkers and highlight the latest developments for their clinical application.
阿尔茨海默病（AD）是老年人中最常见的痴呆症病因，由于无法针对有效的治疗窗口期，因此尝试开发疗法均未成功。中枢神经系统（CNS）生物标志物具有洞察力，但不适合用于高通量基于人群的筛查。因此，AD 的外周血生物标志物将极大地改善早期诊断，有可能实现无症状检测，并有助于有效靶向疾病修饰治疗。血液的各种成分，包括血浆、血小板和细胞部分，现在正被系统地探索作为 AD 潜在外周生物标志物的来源。在本综述中，我们介绍了一些鲜为人知的外周生物标志物，并强调了其临床应用的最新进展。
